{"product_id":"sybrava-pre-filled-solution-for-injection","title":"Sybrava Pre-Filled Solution for Injection","description":"\u003ch3 data-start=\"296\" data-end=\"321\"\u003eWhat is Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"322\" data-end=\"706\"\u003e\u003cstrong data-start=\"322\" data-end=\"336\"\u003eInclisiran\u003c\/strong\u003e is an innovative small interfering RNA (siRNA) therapeutic designed to lower low‑density lipoprotein cholesterol (LDL‑C) by inhibiting the hepatic production of proprotein convertase subtilisin\/kexin type 9 (PCSK9). By reducing PCSK9 levels, inclisiran increases the number of LDL receptors on hepatocytes, thereby enhancing the clearance of LDL‑C from the bloodstream.\u003c\/p\u003e\r\n\u003cp data-start=\"708\" data-end=\"868\"\u003e\u003cem data-start=\"708\" data-end=\"868\"\u003eReference: U.S. Food and Drug Administration (FDA) \u003ca href=\"https:\/\/www.fda.gov\" target=\"_new\" rel=\"noopener\" data-start=\"760\" data-end=\"813\"\u003eLeqvio Prescribing Information\u003c\/a\u003e; ClinicalTrials.gov ORION studies (e.g., NCT03397194)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"870\" data-end=\"873\"\u003e\r\n\u003ch3 data-start=\"875\" data-end=\"929\"\u003eWhat are the other popular names for Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"930\" data-end=\"1092\"\u003eInclisiran is primarily marketed under the brand name \u003cstrong data-start=\"984\" data-end=\"995\"\u003eLeqvio®\u003c\/strong\u003e. In clinical discussions and literature, it is also referred to by its generic name, inclisiran.\u003c\/p\u003e\r\n\u003cp data-start=\"1094\" data-end=\"1148\"\u003e\u003cem data-start=\"1094\" data-end=\"1148\"\u003eReference: U.S. FDA; MedlinePlus; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1150\" data-end=\"1153\"\u003e\r\n\u003ch3 data-start=\"1155\" data-end=\"1207\"\u003eWhat is the drug classification of Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"1208\" data-end=\"1449\"\u003eInclisiran is classified as an \u003cstrong data-start=\"1239\" data-end=\"1278\"\u003eRNA interference (RNAi) therapeutic\u003c\/strong\u003e and is grouped as a \u003cstrong data-start=\"1299\" data-end=\"1318\"\u003ePCSK9 inhibitor\u003c\/strong\u003e. Unlike traditional monoclonal antibody PCSK9 inhibitors, inclisiran uses siRNA technology to reduce PCSK9 synthesis in the liver.\u003c\/p\u003e\r\n\u003cp data-start=\"1451\" data-end=\"1536\"\u003e\u003cem data-start=\"1451\" data-end=\"1536\"\u003eReference: World Health Organization (WHO) guidelines on lipid management; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1538\" data-end=\"1541\"\u003e\r\n\u003ch3 data-start=\"1543\" data-end=\"1590\"\u003eWhat is the mode of action of Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"1591\" data-end=\"2033\"\u003eInclisiran works by entering hepatocytes and incorporating into the RNA-induced silencing complex (RISC). Once loaded into RISC, it specifically binds to the messenger RNA (mRNA) that encodes PCSK9, leading to its degradation. As a result, less PCSK9 protein is produced, which increases the recycling and expression of LDL receptors on liver cells. This enhanced receptor activity facilitates greater clearance of LDL‑C from the circulation.\u003c\/p\u003e\r\n\u003cp data-start=\"2035\" data-end=\"2108\"\u003e\u003cem data-start=\"2035\" data-end=\"2108\"\u003eReference: PubMed (e.g., Ray et al., 2017 on RNAi mechanisms); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2110\" data-end=\"2113\"\u003e\r\n\u003ch3 data-start=\"2115\" data-end=\"2161\"\u003eWhat are the primary uses of Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"2162\" data-end=\"2263\"\u003eInclisiran is used as an adjunct to diet and maximally tolerated statin therapy for the treatment of:\u003c\/p\u003e\r\n\u003cul data-start=\"2264\" data-end=\"2439\"\u003e\r\n\u003cli data-start=\"2264\" data-end=\"2319\"\u003e\u003cstrong data-start=\"2266\" data-end=\"2319\"\u003eHeterozygous Familial Hypercholesterolemia (HeFH)\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"2320\" data-end=\"2439\"\u003e\n\u003cstrong data-start=\"2322\" data-end=\"2372\"\u003eAtherosclerotic Cardiovascular Disease (ASCVD)\u003c\/strong\u003e\u003cbr data-start=\"2372\" data-end=\"2375\"\u003eIt is indicated in adults who require additional LDL‑C lowering.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2441\" data-end=\"2520\"\u003e\u003cem data-start=\"2441\" data-end=\"2520\"\u003eReference: U.S. FDA; ClinicalTrials.gov (ORION-9, ORION-10, ORION-11 studies)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2522\" data-end=\"2525\"\u003e\r\n\u003ch3 data-start=\"2527\" data-end=\"2598\"\u003eWhat is the recommended dosage and administration for Inclisiran?\u003c\/h3\u003e\r\n\u003cul data-start=\"2599\" data-end=\"2949\"\u003e\r\n\u003cli data-start=\"2599\" data-end=\"2780\"\u003e\n\u003cstrong data-start=\"2601\" data-end=\"2612\"\u003eDosage:\u003c\/strong\u003e\r\n\u003cul data-start=\"2617\" data-end=\"2780\"\u003e\r\n\u003cli data-start=\"2617\" data-end=\"2780\"\u003eThe recommended regimen is two subcutaneous injections in the first year—one at Day 0 and a second at Day 90—followed by maintenance injections every six months.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"2781\" data-end=\"2949\"\u003e\n\u003cstrong data-start=\"2783\" data-end=\"2802\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2807\" data-end=\"2949\"\u003e\r\n\u003cli data-start=\"2807\" data-end=\"2949\"\u003eInclisiran is administered by subcutaneous injection. Consistency in the injection schedule is key to maintaining its LDL‑C–lowering effect.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2951\" data-end=\"3081\"\u003e\u003cem data-start=\"2951\" data-end=\"3081\"\u003eReference: U.S. FDA \u003ca href=\"https:\/\/www.fda.gov\" target=\"_new\" rel=\"noopener\" data-start=\"2972\" data-end=\"3025\"\u003eLeqvio Prescribing Information\u003c\/a\u003e; ClinicalTrials.gov (e.g., ORION‑10 study NCT03399370)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3083\" data-end=\"3086\"\u003e\r\n\u003ch3 data-start=\"3088\" data-end=\"3151\"\u003eWhat prescribing information is important for Inclisiran?\u003c\/h3\u003e\r\n\u003cul data-start=\"3152\" data-end=\"3683\"\u003e\r\n\u003cli data-start=\"3152\" data-end=\"3333\"\u003e\n\u003cstrong data-start=\"3154\" data-end=\"3170\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3175\" data-end=\"3333\"\u003e\r\n\u003cli data-start=\"3175\" data-end=\"3333\"\u003eInclisiran is indicated for patients with HeFH or established ASCVD who need additional LDL‑C reduction despite being on maximally tolerated statin therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3334\" data-end=\"3427\"\u003e\n\u003cstrong data-start=\"3336\" data-end=\"3358\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3363\" data-end=\"3427\"\u003e\r\n\u003cli data-start=\"3363\" data-end=\"3427\"\u003eKnown hypersensitivity to inclisiran or any of its components.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3428\" data-end=\"3548\"\u003e\n\u003cstrong data-start=\"3430\" data-end=\"3445\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3450\" data-end=\"3548\"\u003e\r\n\u003cli data-start=\"3450\" data-end=\"3548\"\u003eRegular monitoring of lipid panels, liver function, and injection site reactions is recommended.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3549\" data-end=\"3683\"\u003e\n\u003cstrong data-start=\"3551\" data-end=\"3578\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3583\" data-end=\"3683\"\u003e\r\n\u003cli data-start=\"3583\" data-end=\"3683\"\u003ePatient education on proper injection technique and adherence to the dosing schedule is essential.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3685\" data-end=\"3774\"\u003e\u003cem data-start=\"3685\" data-end=\"3774\"\u003eReference: U.S. FDA; National Institutes of Health (NIH) guidelines on lipid management\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3776\" data-end=\"3779\"\u003e\r\n\u003ch3 data-start=\"3781\" data-end=\"3880\"\u003eWhat safety information, side effects, warnings, and cautions are associated with Inclisiran?\u003c\/h3\u003e\r\n\u003cul data-start=\"3881\" data-end=\"4731\"\u003e\r\n\u003cli data-start=\"3881\" data-end=\"4021\"\u003e\n\u003cstrong data-start=\"3883\" data-end=\"3907\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3912\" data-end=\"4021\"\u003e\r\n\u003cli data-start=\"3912\" data-end=\"3973\"\u003eInjection site reactions (e.g., redness, pain, or swelling)\u003c\/li\u003e\r\n\u003cli data-start=\"3976\" data-end=\"4021\"\u003eMild nasopharyngitis or flu-like symptoms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4022\" data-end=\"4158\"\u003e\n\u003cstrong data-start=\"4024\" data-end=\"4061\"\u003eLess Common\/Serious Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4066\" data-end=\"4158\"\u003e\r\n\u003cli data-start=\"4066\" data-end=\"4091\"\u003eRare allergic reactions\u003c\/li\u003e\r\n\u003cli data-start=\"4094\" data-end=\"4158\"\u003eTransient elevations in liver enzymes (monitoring recommended)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4159\" data-end=\"4572\"\u003e\n\u003cstrong data-start=\"4161\" data-end=\"4185\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4190\" data-end=\"4572\"\u003e\r\n\u003cli data-start=\"4190\" data-end=\"4290\"\u003e\n\u003cstrong data-start=\"4192\" data-end=\"4221\"\u003eInjection Site Reactions:\u003c\/strong\u003e Patients should be advised about the possibility of local reactions.\u003c\/li\u003e\r\n\u003cli data-start=\"4293\" data-end=\"4439\"\u003e\n\u003cstrong data-start=\"4295\" data-end=\"4314\"\u003eLiver Function:\u003c\/strong\u003e Although systemic exposure is low, periodic liver function tests are advised in patients with pre-existing liver conditions.\u003c\/li\u003e\r\n\u003cli data-start=\"4442\" data-end=\"4572\"\u003e\n\u003cstrong data-start=\"4444\" data-end=\"4472\"\u003ePregnancy and Lactation:\u003c\/strong\u003e Inclisiran is not recommended during pregnancy or breastfeeding due to insufficient data on safety.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4573\" data-end=\"4731\"\u003e\n\u003cstrong data-start=\"4575\" data-end=\"4599\"\u003eAdditional Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4604\" data-end=\"4731\"\u003e\r\n\u003cli data-start=\"4604\" data-end=\"4731\"\u003eBecause inclisiran is administered infrequently (every six months after initial dosing), adherence to follow-up is essential.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4733\" data-end=\"4816\"\u003e\u003cem data-start=\"4733\" data-end=\"4816\"\u003eReference: U.S. FDA \u003ca href=\"https:\/\/www.fda.gov\" target=\"_new\" rel=\"noopener\" data-start=\"4754\" data-end=\"4807\"\u003eLeqvio Prescribing Information\u003c\/a\u003e; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4818\" data-end=\"4821\"\u003e\r\n\u003ch3 data-start=\"4823\" data-end=\"4889\"\u003eWhat drug interactions should be considered with Inclisiran?\u003c\/h3\u003e\r\n\u003cul data-start=\"4890\" data-end=\"5584\"\u003e\r\n\u003cli data-start=\"4890\" data-end=\"5167\"\u003e\n\u003cstrong data-start=\"4892\" data-end=\"4933\"\u003eConcomitant Lipid-Lowering Therapies:\u003c\/strong\u003e\r\n\u003cul data-start=\"4938\" data-end=\"5167\"\u003e\r\n\u003cli data-start=\"4938\" data-end=\"5167\"\u003eInclisiran is designed to be used in combination with maximally tolerated statin therapy. There are no major drug interactions that contraindicate its use with other lipid‑lowering agents; rather, its effects are complementary.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5168\" data-end=\"5391\"\u003e\n\u003cstrong data-start=\"5170\" data-end=\"5198\"\u003eImmunomodulatory Agents:\u003c\/strong\u003e\r\n\u003cul data-start=\"5203\" data-end=\"5391\"\u003e\r\n\u003cli data-start=\"5203\" data-end=\"5391\"\u003eAlthough inclisiran is an siRNA therapeutic with a targeted mechanism, always inform the healthcare provider of all concurrent medications to ensure there are no unforeseen interactions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5392\" data-end=\"5584\"\u003e\n\u003cstrong data-start=\"5394\" data-end=\"5420\"\u003eGeneral Consideration:\u003c\/strong\u003e\r\n\u003cul data-start=\"5425\" data-end=\"5584\"\u003e\r\n\u003cli data-start=\"5425\" data-end=\"5584\"\u003eDue to its specific mechanism of action (RNA interference), inclisiran has a low potential for typical drug–drug interactions seen with small molecule drugs.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5586\" data-end=\"5651\"\u003e\u003cem data-start=\"5586\" data-end=\"5651\"\u003eReference: U.S. FDA; ClinicalTrials.gov (ORION studies); PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5653\" data-end=\"5656\"\u003e\r\n\u003ch3 data-start=\"5658\" data-end=\"5711\"\u003eWhat FAQs might patients have about Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"5713\" data-end=\"6033\"\u003e\u003cstrong data-start=\"5713\" data-end=\"5789\"\u003eQ: How does Inclisiran differ from monoclonal antibody PCSK9 inhibitors?\u003c\/strong\u003e\u003cbr data-start=\"5789\" data-end=\"5792\"\u003eA: Unlike monoclonal antibodies, which bind circulating PCSK9, inclisiran uses siRNA technology to reduce PCSK9 production at the genetic level, offering a prolonged effect with just two initial doses and maintenance dosing every six months.\u003c\/p\u003e\r\n\u003cp data-start=\"6035\" data-end=\"6257\"\u003e\u003cstrong data-start=\"6035\" data-end=\"6088\"\u003eQ: How effective is Inclisiran in lowering LDL‑C?\u003c\/strong\u003e\u003cbr data-start=\"6088\" data-end=\"6091\"\u003eA: Clinical trials (e.g., ORION‑10 and ORION‑11) have shown that inclisiran can reduce LDL‑C levels by approximately 50% when used in conjunction with statin therapy.\u003c\/p\u003e\r\n\u003cp data-start=\"6259\" data-end=\"6456\"\u003e\u003cstrong data-start=\"6259\" data-end=\"6313\"\u003eQ: What are the common side effects of Inclisiran?\u003c\/strong\u003e\u003cbr data-start=\"6313\" data-end=\"6316\"\u003eA: The most common side effects include injection site reactions, such as mild redness or swelling, and occasionally mild flu-like symptoms.\u003c\/p\u003e\r\n\u003cp data-start=\"6458\" data-end=\"6626\"\u003e\u003cstrong data-start=\"6458\" data-end=\"6508\"\u003eQ: Is Inclisiran safe to use during pregnancy?\u003c\/strong\u003e\u003cbr data-start=\"6508\" data-end=\"6511\"\u003eA: Inclisiran is not recommended during pregnancy or breastfeeding due to limited safety data in these populations.\u003c\/p\u003e\r\n\u003cp data-start=\"6628\" data-end=\"6804\"\u003e\u003cstrong data-start=\"6628\" data-end=\"6666\"\u003eQ: How is Inclisiran administered?\u003c\/strong\u003e\u003cbr data-start=\"6666\" data-end=\"6669\"\u003eA: It is given as a subcutaneous injection—an initial dose, a second dose at 90 days, and then maintenance injections every six months.\u003c\/p\u003e\r\n\u003cp data-start=\"6806\" data-end=\"6908\"\u003e\u003cem data-start=\"6806\" data-end=\"6908\"\u003eReference: U.S. FDA; ClinicalTrials.gov (ORION‑10, ORION‑11); New England Journal of Medicine (NEJM)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6910\" data-end=\"6913\"\u003e\r\n\u003ch3 data-start=\"6915\" data-end=\"7009\"\u003eWhere can I find additional clinical evidence and detailed information about Inclisiran?\u003c\/h3\u003e\r\n\u003cp data-start=\"7010\" data-end=\"7104\"\u003eFor further details on clinical studies, dosing guidelines, and safety monitoring, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"7105\" data-end=\"7466\"\u003e\r\n\u003cli data-start=\"7105\" data-end=\"7193\"\u003e\n\u003cstrong data-start=\"7107\" data-end=\"7159\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"7160\" data-end=\"7191\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"7194\" data-end=\"7264\"\u003e\n\u003cstrong data-start=\"7196\" data-end=\"7219\"\u003eClinicalTrials.gov:\u003c\/strong\u003e (e.g., ORION‑9, ORION‑10, ORION‑11 trials)\u003c\/li\u003e\r\n\u003cli data-start=\"7265\" data-end=\"7359\"\u003e\n\u003cstrong data-start=\"7267\" data-end=\"7310\"\u003eNew England Journal of Medicine (NEJM):\u003c\/strong\u003e Publications on inclisiran efficacy and safety\u003c\/li\u003e\r\n\u003cli data-start=\"7360\" data-end=\"7466\"\u003e\n\u003cstrong data-start=\"7362\" data-end=\"7435\"\u003eWorld Health Organization (WHO) and American Heart Association (AHA):\u003c\/strong\u003e Guidelines on lipid management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7468\" data-end=\"7525\"\u003e\u003cem data-start=\"7468\" data-end=\"7525\"\u003eReference: U.S. FDA; ClinicalTrials.gov; NEJM; WHO; AHA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7527\" data-end=\"7530\"\u003e\r\n\u003ch3 data-start=\"7532\" data-end=\"7552\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"7553\" data-end=\"8292\"\u003e\u003cstrong data-start=\"7553\" data-end=\"7577\"\u003eInclisiran (Leqvio®)\u003c\/strong\u003e is a groundbreaking siRNA therapeutic that offers significant LDL‑C reduction in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease when added to standard lipid‑lowering therapy. With its unique dosing regimen—an initial two-dose series followed by biannual maintenance injections—it provides a convenient treatment option that can enhance patient adherence. Although inclisiran is generally well tolerated, proper patient selection, monitoring of liver function, and adherence to injection schedules are critical to maximize its benefits while minimizing potential risks. Always consult your healthcare provider to determine if inclisiran is appropriate for your treatment plan.\u003c\/p\u003e\r\n\u003cp data-start=\"8294\" data-end=\"8518\"\u003e\u003cem data-start=\"8294\" data-end=\"8518\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"284mg","offer_id":51736357896475,"sku":"Sybrava Pre-Filled Solution for Injection-284mg","price":2460.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0992\/3303\/8619\/files\/untitled_design_69.png?v=1770434131","url":"https:\/\/ezchemist.com\/products\/sybrava-pre-filled-solution-for-injection","provider":"EZ Chemist","version":"1.0","type":"link"}